STAT Plus: A stem cell company is touting a stroke survivor’s recovery. Its media blitz offers investors a mirage By ADAM FEUERSTEIN

STAT Plus: A stem cell company is touting a stroke survivor’s recovery. Its media blitz offers investors a mirage

By ADAM FEUERSTEIN

ADOBE, DOM SMITH/STAT

A promotional campaign by Athersys, a small drug maker, for an experimental stem cell therapy ignores the available scientific evidence and clinical data.

READ MORE